Whereas some people fear dilution, I'm actually hoping that it will happen soon because I think the delay is helping to keep the sp down due to many investors, like Fred, who are sitting on the sidelines out of the concern that it will hurt the sp. We're way too close to getting the PE combo results for dilution to have any long-term effect. And given that all recent cash raises were relatively small, I believe mgmt will continue to try to ride the waves, and only further dilute to raise just enough cash to cover us to the next event, which may be when they release the PE data, or the end of Oct (due to the Oct 17 meeting with the FDA). And in late Oct or early Nov, I would expect another minor dilution to get us to the end of the year when they expect to complete enrollment for the mono trial. Why raise a significant amount of cash now if they may not need it due to a BO which could happen at any time? This is all speculation on my part, but I've been here long enough to see how mgmt is playing the game. I also think there's much more risk in sitting on the sidelines and missing out on a possible BO, than experiencing future dilution that will continue to fund two ongoing P3 trials for a drug that may be worth billions in future revenue to a BP. I realize everyone has their own level of risk tolerance, but one has to decide which is more riskier - missing out on a binary event, or future dilution.
Market Data 
Markets 
AI
